{"gene":"BCLAF1","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1999,"finding":"BCLAF1 (Btf) was identified as a novel protein that interacts with the antiapoptotic proteins E1B 19K, Bcl-2, and Bcl-xL (but not proapoptotic Bax) via yeast two-hybrid screening. Btf contains homology to bZIP and Myb DNA-binding domains, binds DNA in vitro, and represses transcription in reporter assays. E1B 19K, Bcl-2, and Bcl-xL sequester Btf in the cytoplasm and block its transcriptional repression activity. Sustained overexpression of Btf in HeLa cells induced apoptosis, which was inhibited by E1B 19K.","method":"Yeast two-hybrid, in vitro DNA binding, reporter transcription assays, overexpression/apoptosis assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — original discovery with multiple orthogonal methods; foundational highly-cited paper","pmids":["10330179"],"is_preprint":false},{"year":2004,"finding":"Emerin (a nuclear membrane protein mutated in Emery-Dreifuss muscular dystrophy) directly binds BCLAF1/Btf with KD ~100 nM. The emerin disease-causing missense mutation S54F selectively disrupts binding to Btf without affecting binding to lamin A or GCL. Upon Fas-induced apoptosis, Btf redistributes from dot-like nuclear structures to a zone near the nuclear envelope, suggesting apoptotic regulation of Btf localization.","method":"Yeast two-hybrid, biochemical binding/affinity measurement, alanine-substitution mutagenesis, indirect immunofluorescence","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — binding affinity measured, mutagenesis, localization studies; highly cited","pmids":["15009215"],"is_preprint":false},{"year":2007,"finding":"PKCδ interacts with BCLAF1/Btf upon DNA damage and co-occupies the TP53 core promoter element (CPE-TP53), driving TP53 transcription. Inhibition of PKCδ activity reduces Btf affinity for CPE-TP53, lowering TP53 mRNA and protein levels. RNAi-mediated disruption of Btf-mediated TP53 transcription suppresses TP53-dependent apoptosis after genotoxic stress.","method":"Reporter assays, Co-IP, ChIP, RNAi knockdown, RT-PCR, Western blot","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, Co-IP, reporter, RNAi) in single lab; strong mechanistic detail","pmids":["17938203"],"is_preprint":false},{"year":2008,"finding":"Bclaf1 knockout mice show defects in lung saccular-stage smooth muscle organization and peripheral T-cell homeostasis, but not thymocyte development. Bclaf1-deficient cells do not show defects in apoptosis after various stimuli, indicating Bclaf1 is required for developmental processes independent of its postulated proapoptotic role.","method":"Targeted gene knockout in mice, histology, FACS analysis of immune cells","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — clean KO mouse with defined cellular phenotypes across multiple tissues","pmids":["19008920"],"is_preprint":false},{"year":2011,"finding":"Sirt1 suppresses BCLAF1 transcription by deacetylating histone H3 lysine 56 (H3K56) at the bclaf1 promoter. Upon TCR/CD28 stimulation, Sirt1 is recruited to the bclaf1 promoter by forming a complex with p300 and NF-κB subunit Rel-A; only p300 (not GCN5) specifically acetylates H3K56 at this promoter. Knockdown of Bclaf1 suppresses hyperactivation of Sirt1-null T cells, placing Bclaf1 downstream of Sirt1 in T cell activation.","method":"ChIP, siRNA knockdown, H3K56 acetylation assay, IL-2 ELISA, proliferation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — ChIP with multiple controls, epistasis via knockdown, clear pathway placement","pmids":["21454709"],"is_preprint":false},{"year":2012,"finding":"BCLAF1 associates with γH2AX in a radiation dose-dependent manner. Under high-dose ionizing radiation, BCLAF1 promotes apoptosis by disrupting p21-mediated inhibition of caspase/cyclin E-dependent mitochondrial pathways and co-localizes with γH2AX foci while stabilizing the Ku70/DNA-PKcs complex to facilitate NHEJ-based DSB repair in surviving cells. In tumor cells, BCLAF1 is suppressed, leading to anti-apoptotic Ku70-Bax complexes and defective NHEJ repair.","method":"Mass spectrometry-based identification, Co-IP, immunofluorescence colocalization, siRNA knockdown, apoptosis assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — MS identification followed by Co-IP, colocalization, functional knockdown with defined phenotypes","pmids":["22833098"],"is_preprint":false},{"year":2012,"finding":"Human cytomegalovirus uses two independent mechanisms to neutralize BCLAF1 as a restriction factor: (1) virion-delivered pp71 and UL35 proteins direct proteasomal degradation of BCLAF1 immediately post-infection; (2) virus-encoded miR-UL112-1 downregulates BCLAF1 at late infection stages. In the absence of BCLAF1 neutralization, viral gene expression and replication are inhibited.","method":"Viral infection assays, siRNA knockdown, proteasome inhibitor treatment, miRNA functional assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — two distinct mechanistic pathways demonstrated with multiple methods","pmids":["22645331"],"is_preprint":false},{"year":2013,"finding":"Btf (BCLAF1) and TRAP150 both localize at active transcription loci in a RNA polymerase II-dependent manner and overlap with the exon junction complex (EJC) protein Magoh. Btf depletion (but not TRAP150 depletion) causes increased cytoplasmic levels of β-tropomyosin reporter transcripts and global increase of endogenous polyadenylated RNA in the cytoplasm, indicating a distinct role for Btf in regulating subcellular mRNA distribution.","method":"Live-cell imaging at reporter loci, siRNA knockdown, nuclear/cytoplasmic fractionation, RT-PCR","journal":"Nucleus (Austin, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiments with functional fractionation consequence, single lab","pmids":["23778535"],"is_preprint":false},{"year":2014,"finding":"The splicing factor SRSF10 stimulates inclusion of BCLAF1 alternative exon 5a, generating a distinct protein isoform. The BCLAF1 isoform resulting from exon 5a inclusion promotes growth and tumorigenic potential of colon cancer cells, while its knockdown inhibits these effects. SRSF10 upregulation in colorectal cancer parallels increased exon 5a inclusion, linking SRSF10-regulated splicing to BCLAF1 oncogenic isoform production.","method":"RT-PCR splicing assays, siRNA knockdown, overexpression, tumor growth assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — splicing mechanism defined, functional consequence validated, replicated in clinical samples; highly cited","pmids":["25091051"],"is_preprint":false},{"year":2016,"finding":"Bclaf1 is upregulated through the ATM/Nemo/NF-κB pathway during doxorubicin-induced senescence and is a direct transcriptional target of p65 and c-Rel. Bclaf1 physically interacts with the leucine zipper region of C/EBPβ and together they upregulate IL-6 and IL-8 transcription to establish the senescence-associated secretory phenotype (SASP). Bclaf1 is thus an NF-κB-to-C/EBPβ transducer in therapy-induced senescence.","method":"ChIP, Co-IP, siRNA knockdown, reporter assays, IL-6/IL-8 ELISA, xenograft model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — direct protein interaction, ChIP, and functional pathway placement with multiple methods","pmids":["26794446"],"is_preprint":false},{"year":2017,"finding":"THRAP3 and BCLAF1 promote the DNA damage response by selectively regulating mRNA splicing and nuclear export of key DDR transcripts, including ATM kinase mRNA. Loss of either protein leads to sensitivity to DNA damaging agents, defective DNA repair, and genomic instability. Cancer-associated mutations in THRAP3 deregulate THRAP3/BCLAF1-controlled transcript processing.","method":"siRNA knockdown, RNA-seq splicing analysis, nuclear export assays, DNA damage sensitivity assays, comet assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, defined mechanism of selective mRNA processing","pmids":["29112714"],"is_preprint":false},{"year":2017,"finding":"Bclaf1 is required for type I interferon (IFNα) signaling: Bclaf1 maintains efficient STAT1 and STAT2 phosphorylation in response to IFNα, directly interacts with ISRE elements and STAT2 to facilitate ISGF3 binding for gene transcription. Alphaherpesvirus US3 protein degrades Bclaf1 to impair IFNα-mediated antiviral defense.","method":"CRISPR/siRNA knockdown, Co-IP, ChIP, STAT phosphorylation assays, viral replication assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — direct interaction with STAT2/ISRE defined, multiple functional assays, viral mechanism characterized","pmids":["30682178"],"is_preprint":false},{"year":2018,"finding":"Bclaf1 promotes HIF1A transcription via its bZIP domain in hepatocellular carcinoma cells under hypoxia, leading to increased downstream VEGFA, TGFB, and EPO expression and angiogenesis. Conversely, HIF-1α increases Bclaf1 levels in hypoxia, forming a positive feedback loop. Bclaf1 knockdown in xenograft tumors reduces HIF-1α levels and microvessel density.","method":"shRNA knockdown, reporter assays with bZIP domain mutants, Western blot, xenograft experiments, ChIP","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — domain-level mechanistic detail, in vivo validation, positive feedback loop defined","pmids":["30367150"],"is_preprint":false},{"year":2018,"finding":"Cry2 interacts specifically with Bclaf1 (not Cry1), and this interaction stabilizes mRNAs encoding cyclin D1 and Tmem176b in myoblasts. Loss of Cry2 or Bclaf1 knockdown recapitulates the same phenotype: premature cell cycle exit and inefficient myotube fusion. Bclaf1 thus acts as a post-transcriptional mRNA stabilizer downstream of the circadian regulator Cry2.","method":"Co-IP, RNA stability assays, siRNA knockdown, cell fusion assays, Cry2 KO mice, muscle regeneration assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — direct interaction, mRNA stabilization mechanism, phenotypic rescue, in vivo validation","pmids":["29466738"],"is_preprint":false},{"year":2019,"finding":"A SPIC/BCLAF1 transcription factor complex is activated by RAG-generated DNA double-strand breaks in pre-B cells. SPIC recruits BCLAF1 to gene-regulatory elements, and the complex displaces PU.1 from chromatin genome-wide and suppresses SYK tyrosine kinase expression, enforcing the transition from large to small pre-B cells.","method":"ChIP-seq, Co-IP, genetic loss-of-function, gene expression profiling, B cell development assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq, Co-IP, and genetic epistasis defining pathway","pmids":["31644907"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of SDS22 shows its leucine-rich repeat domain adopts a banana-shaped fold with a large basic surface patch that enables binding of a phosphorylated form of BCLAF1. Biochemical studies show SDS22 acts as a 'third' subunit of multiple PP1 holoenzymes and recruits additional interactors such as phosphorylated BCLAF1.","method":"X-ray crystallography, biochemical binding studies","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with biochemical validation of BCLAF1-SDS22 interaction","pmids":["30661852"],"is_preprint":false},{"year":2020,"finding":"Bclaf1 is a direct transcriptional target of HIF-1 and is upregulated during hypoxia. Bclaf1 binds HIF-1α in the nucleus, and this interaction stabilizes HIF-1α protein during long-term hypoxia, protecting it from degradation. Bclaf1 knockout cells show reduced HIF-1α stability and impaired HIF-1 target gene induction; Bclaf1 knockout xenografts show reduced tumor growth with decreased HIF-1α.","method":"ChIP, Co-IP, protein stability assays, CRISPR knockout, xenograft experiments","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — direct nuclear interaction defined, CRISPR KO, in vivo validation","pmids":["32029898"],"is_preprint":false},{"year":2021,"finding":"The long noncoding RNA lncCIRBIL directly binds to Bclaf1 and inhibits its nuclear translocation. Cardiomyocyte-specific transgenic overexpression of lncCIRBIL reduces cardiac infarct area after ischemia-reperfusion (I/R) injury, while Bclaf1 transgenic overexpression worsens I/R injury. Partial Bclaf1 knockout abrogates the detrimental effects of lncCIRBIL knockout, placing Bclaf1 downstream of lncCIRBIL in cardiac I/R injury.","method":"RNA-protein binding assay, nuclear fractionation, transgenic mouse models, Bclaf1 KO, infarct area measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — direct RNA-protein interaction, genetic epistasis via multiple transgenic models, in vivo functional readout","pmids":["33483496"],"is_preprint":false},{"year":2021,"finding":"Bclaf1 exerts anti-apoptotic function in TNF signaling by promoting transcription of CFLAR (c-FLIP), a caspase-8 antagonist. Bclaf1 binds the p50 subunit of NF-κB, and this interaction is required for Bclaf1 to stimulate CFLAR transcription. Bclaf1 depletion sensitizes cells to TNF-induced apoptosis but not necroptosis, and in mice, siRNA-mediated Bclaf1 depletion aggravates TNF-induced intestinal injury.","method":"Co-IP, ChIP, siRNA knockdown, apoptosis/necroptosis assays, in vivo siRNA administration","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — direct interaction with NF-κB p50, ChIP at CFLAR promoter, pathway placement, in vivo validation","pmids":["34693625"],"is_preprint":false},{"year":2022,"finding":"BCLAF1 interacts with SPOP (an E3 ligase adaptor) through an SPOP-binding consensus (SBC) motif on BCLAF1, competitively inhibiting SPOP-mediated ubiquitination and degradation of PD-L1. Mutation of the BCLAF1-SBC motif disrupts BCLAF1-SPOP interaction and abolishes BCLAF1-mediated PD-L1 stabilization. BCLAF1 depletion reduces PD-L1 expression and promotes T cell-mediated cytotoxicity.","method":"Co-IP, site-directed mutagenesis (SBC motif), ubiquitination assay, PD-L1 stability assay, T cell co-culture cytotoxicity","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic mutagenesis of interaction motif, direct ubiquitination competition assay, functional readout","pmids":["38340178"],"is_preprint":false},{"year":2022,"finding":"TET2 and BCLAF1 form a transcription repression complex in colorectal cancer cells, identified by LC-MS/MS, co-IP, immunofluorescence colocalization, and proximity ligation assays. The TET2-BCLAF1 complex binds to the Ascl2 promoter and restrains its hypermethylation by inducing hydroxymethylation at CCGG sites, regulating Ascl2-dependent stem gene expression.","method":"LC-MS/MS, Co-IP, immunofluorescence colocalization, PLA, ChIP-qPCR, glucosylated hydroxymethyl-sensitive qPCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — complex identified by MS and multiple orthogonal confirmation methods; direct epigenetic mechanism defined","pmids":["35660018"],"is_preprint":false},{"year":2022,"finding":"BCLAF1 regulates smooth muscle cell (SMC) survival and lipid transdifferentiation in atherosclerosis. BCLAF1 silencing leads to downregulation of BCL2 and SMC markers, reduced proliferation, and increased apoptosis. BCLAF1 interacts with BCL2 by proximity ligation assay in CD68+ cells of SMC origin in plaques. BCLAF1 knockdown prevents oxLDL-induced SMC transdifferentiation to macrophage-like phenotype.","method":"siRNA knockdown, proximity ligation assay, immunohistochemistry, MYH11 lineage-tracing atherosclerotic mice","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — PLA interaction, functional knockdown, in vivo lineage tracing; single lab","pmids":["35321563"],"is_preprint":false},{"year":2023,"finding":"Cross-linking mass spectrometry (XL-MS) of endogenous proteins revealed that Bclaf1, Thrap3, and Erh interact closely with each other, with interaction surfaces mapped to non-disordered portions of these largely disordered proteins, suggesting they form a novel TEB complex.","method":"Cross-linking mass spectrometry (XL-MS) with DSSO crosslinker after immunoprecipitation of endogenous proteins","journal":"Wellcome open research","confidence":"Medium","confidence_rationale":"Tier 2 — structural topology of endogenous complex by XL-MS, but single method and no functional follow-up","pmids":["35865489"],"is_preprint":false},{"year":2023,"finding":"BCLAF1 interacts with Cullin 3 (CUL3), and through this interaction BCLAF1 promotes ubiquitination and degradation of PHD2 (prolyl hydroxylase domain protein 2), leading to HIF-1α accumulation under normoxic conditions and upregulation of PD-L1 transcription.","method":"Co-IP, immunofluorescence, Western blot, RT-qPCR, ubiquitination assay","journal":"Cancer immunology, immunotherapy : CII","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, Co-IP-based interaction with functional downstream readout","pmids":["37906282"],"is_preprint":false},{"year":2024,"finding":"BCLAF1 interacts with YTHDF2 (an m6A reader protein) in esophageal squamous cell carcinoma, as identified by mass spectrometry, co-immunoprecipitation, and GST pull-down. BCLAF1 reduces YTHDF2 tumor-suppressive activity, and this promotes SIX1 mRNA stability and expression (via reduced m6A-dependent degradation), enhancing glycolysis and cancer progression.","method":"Mass spectrometry, Co-IP, GST pull-down, MeRIP-seq, RIP-seq, transcriptomic analysis","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1-2 — interaction confirmed by multiple methods including GST pull-down and MeRIP-seq for mechanism","pmids":["38636894"],"is_preprint":false},{"year":2024,"finding":"BCLAF1 interacts with BACH1 (BRCA1-associated C-terminal helicase) constitutively; upon DNA damage, BCLAF1 is recruited to DNA damage sites in a BACH1- and BRCA1-dependent manner. BCLAF1-deficient cells are defective in DSB-initiated homologous recombination (HR), although RAD51 foci formation is intact.","method":"Tandem protein affinity purification, Co-IP, immunofluorescence (DNA damage foci), siRNA knockdown, HR reporter assay","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 2 — direct interaction and recruitment defined, genetic epistasis for HR, single lab","pmids":["35930920"],"is_preprint":false},{"year":2024,"finding":"BCLAF1 interacts with LAMTOR2, and this interaction regulates the nuclear translocation of BCLAF1. In osteoarthritis, BCLAF1 is upregulated in chondrocytes and promotes catabolic gene expression and apoptosis; BCLAF1 knockdown via intra-articular adeno-associated virus attenuates cartilage degradation in vivo.","method":"Co-IP, mass spectrometry, subcellular fractionation, adenoviral shRNA in vivo, OA mouse model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — interaction identified by IP/MS with functional consequence, in vivo validation, single lab","pmids":["39990659"],"is_preprint":false},{"year":2024,"finding":"MED23 (a mediator complex subunit) interacts with BCLAF1, and this MED23/BCLAF1 complex regulates NUPR1 transcription in NSCLC cells. Loss of MED23 triggers premature senescence through disrupted autophagic flux dependent on NUPR1 expression downstream of the complex.","method":"Co-IP, mass spectrometry, PLA, RNA-seq, ChIP assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — interaction validated by co-IP and PLA, downstream target validated by ChIP, single lab","pmids":["39366174"],"is_preprint":false},{"year":2025,"finding":"Nuclear p85β (regulatory subunit of PI3K) physically interacts with BCLAF1 and co-occupies gene loci genome-wide. BCLAF1 recruits p85β to BCLAF1 gene loci, and p85β facilitates assembly of BCLAF1, TRIM28, and ZNF263 to activate BCLAF1 transcription in a positive autoregulatory loop. This nuclear function of p85β/BCLAF1 contributes to oncogenic gene transcription.","method":"Multi-omics (ChIP-seq, proteomics), Co-IP, knockdown, reporter assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multi-omics co-occupancy, direct interaction, autoregulatory mechanism with multiple validations","pmids":["40016211"],"is_preprint":false},{"year":2025,"finding":"BCLAF1 physically associates with core spliceosome components and regulates alternative splicing with a predominant effect on intron retention. BCLAF1 is required for productive splicing of ATF4 mRNA, thereby sustaining ATF4 protein expression. Loss of BCLAF1 reduces ATF4 protein levels, downregulates metabolic target genes, disrupts de novo amino acid biosynthesis, and sensitizes AML cells to venetoclax.","method":"Co-IP (spliceosome components), RNA-seq splicing analysis, BCLAF1 depletion, ATF4 protein/mRNA analysis, metabolic assays, drug sensitivity assay","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — preprint with direct interaction, splicing mechanism, and metabolic consequence; awaiting peer review","pmids":["41648520"],"is_preprint":true},{"year":2025,"finding":"Bclaf1 undergoes liquid-liquid phase separation (LLPS) in cardiomyocytes under oxidative stress, forming biomolecular condensates in the nucleus that sequester PTK2 (FAK). PTK2 within Bclaf1 condensates is protected from ubiquitin-proteasome system (UPS)-mediated degradation at the K926 ubiquitination site. Disruption of Bclaf1 condensates leads to PTK2 degradation, increased p53 levels, and apoptosis.","method":"Advanced fluorescence microscopy (LLPS visualization), Co-IP, ubiquitination site mapping (K926), proteasome inhibition, Bclaf1 knockdown","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 2-3 — preprint, novel LLPS mechanism; awaiting peer review and independent replication","pmids":["bio_10.1101_2025.02.04.636487"],"is_preprint":true},{"year":2025,"finding":"BCKDK (branched-chain ketoacid dehydrogenase kinase) interacts with BCLAF1 and promotes its phosphorylation at serine 285, which facilitates BCLAF1 binding to the MYC promoter to enhance MYC transcription, driving HK2-dependent aerobic glycolysis and Trametinib resistance in lung cancer.","method":"Co-IP, phosphorylation assay (S285 site), ChIP at MYC promoter, BCKDK/BCLAF1 knockdown, glycolysis assay","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — direct interaction, phosphorylation site identified, ChIP validation; single lab","pmids":["40442441"],"is_preprint":false},{"year":2017,"finding":"Depletion of Btf (BCLAF1) and/or TRAP150 causes mitotic chromosome misalignment defects in human cells, associated with altered abundance of transcripts encoding mitotic checkpoint regulators, indicating BCLAF1 controls mitotic progression through regulating mitotic regulator mRNA levels.","method":"siRNA knockdown, live-cell microscopy, RT-PCR for mitotic regulator transcripts","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct functional link between BCLAF1 depletion and mitotic defects, but mechanistic detail limited to transcript levels","pmids":["28895891"],"is_preprint":false},{"year":2025,"finding":"Bclaf1 promotes chromatin accessibility in esophageal carcinogenesis by activating POLR2A (RNA polymerase II subunit) through two mechanisms: (1) transcriptionally, Bclaf1/P300/H3K27ac co-recruitment at the POLR2A super-enhancer (E2/E3 elements) drives transcription; (2) post-transcriptionally, Bclaf1 cofactor SNRPA interacts with pre-POLR2A mRNA to regulate its splicing.","method":"ATAC-seq, CUT&Tag, RIP assay, ChIP, siRNA knockdown, ATAC-seq after Bclaf1 silencing","journal":"Journal of hazardous materials","confidence":"Medium","confidence_rationale":"Tier 2 — multiple epigenomic methods defining dual transcriptional/splicing mechanism; single lab","pmids":["40220379"],"is_preprint":false}],"current_model":"BCLAF1 is a multifunctional nuclear protein that acts as a transcriptional activator or repressor (via its bZIP domain), an mRNA splicing regulator associated with the spliceosome, and an mRNA stability/export factor; it interacts with Bcl-2 family members, NF-κB subunits (p50/p65), STAT2, HIF-1α, SPOP E3 ligase, the EJC, PP1/SDS22, and multiple splicing factors to regulate apoptosis, the DNA damage response (via γH2AX/Ku70/DNA-PKcs and NHEJ), type I interferon signaling, cellular senescence, hypoxic adaptation (HIF-1α stabilization), immune checkpoint (PD-L1 stabilization via SPOP competition), and developmental processes including lung morphogenesis, T-cell activation, and B-cell development."},"narrative":{"teleology":[{"year":1999,"claim":"The discovery of BCLAF1 established it as a Bcl-2/Bcl-xL-interacting nuclear protein with DNA-binding and transcriptional repression activity whose overexpression induces apoptosis, providing the founding link between anti-apoptotic Bcl-2 family members and a transcription factor.","evidence":"Yeast two-hybrid, in vitro DNA binding, reporter assays, and overexpression apoptosis assays in HeLa cells","pmids":["10330179"],"confidence":"High","gaps":["Endogenous transcriptional targets unidentified","Mechanism of Bcl-2/Bcl-xL cytoplasmic sequestration unclear at molecular level","Physiological relevance of proapoptotic activity not tested in vivo"]},{"year":2004,"claim":"Identification of emerin as a high-affinity BCLAF1 binding partner, with a disease-causing emerin mutation selectively disrupting this interaction, revealed that BCLAF1 connects to nuclear envelope biology and suggested its subnuclear relocalization during apoptosis.","evidence":"Yeast two-hybrid, biochemical affinity measurement (KD ~100 nM), mutagenesis, immunofluorescence during Fas-induced apoptosis","pmids":["15009215"],"confidence":"High","gaps":["Functional consequence of emerin-BCLAF1 interaction on gene expression undefined","Whether BCLAF1 contributes to Emery-Dreifuss muscular dystrophy pathogenesis untested"]},{"year":2007,"claim":"Demonstrating that PKCδ partners with BCLAF1 at the TP53 promoter after DNA damage established BCLAF1 as a direct transcriptional activator of a specific endogenous target (TP53), resolving the question of what genes BCLAF1 regulates.","evidence":"ChIP, Co-IP, reporter assays, RNAi knockdown, RT-PCR in genotoxically stressed cells","pmids":["17938203"],"confidence":"High","gaps":["Whether BCLAF1 binds TP53 promoter independently of PKCδ unknown","Genome-wide scope of BCLAF1 transcriptional targets not yet mapped"]},{"year":2008,"claim":"Bclaf1 knockout mice revealed essential developmental roles in lung morphogenesis and peripheral T-cell homeostasis but no overt apoptosis defect, fundamentally reframing BCLAF1 from a dedicated proapoptotic factor to a pleiotropic regulator.","evidence":"Targeted gene knockout in mice, histology, FACS analysis","pmids":["19008920"],"confidence":"High","gaps":["Molecular targets mediating lung and T-cell phenotypes not identified","Conditional tissue-specific knockouts not performed"]},{"year":2011,"claim":"Placing BCLAF1 as a Sirt1/NF-κB-regulated downstream effector in T-cell activation explained how BCLAF1 transcription itself is controlled and linked it to chromatin remodeling (H3K56 acetylation) at its own promoter.","evidence":"ChIP for H3K56ac, siRNA epistasis, IL-2 ELISA in Sirt1-null T cells","pmids":["21454709"],"confidence":"High","gaps":["Whether Sirt1-BCLAF1 axis operates outside T cells unclear","Downstream BCLAF1 targets in T-cell activation undefined"]},{"year":2012,"claim":"Two parallel advances established BCLAF1's roles in DNA damage signaling — promoting γH2AX-associated NHEJ repair via Ku70/DNA-PKcs stabilization — and in antiviral defense, where HCMV evolved two independent strategies (pp71/UL35-mediated degradation and miR-UL112-1 silencing) to neutralize BCLAF1 as a restriction factor.","evidence":"MS-based identification, Co-IP, colocalization with γH2AX, siRNA knockdown for DDR; viral infection assays, proteasome inhibitors, miRNA assays for HCMV","pmids":["22833098","22645331"],"confidence":"High","gaps":["Whether BCLAF1 participates in HR in addition to NHEJ not addressed","Identity of BCLAF1-regulated antiviral genes not determined","Structural basis of Ku70/DNA-PKcs stabilization unknown"]},{"year":2013,"claim":"Localization of BCLAF1 at active transcription loci in an RNA Pol II-dependent manner, overlapping with EJC component Magoh, and the finding that its depletion increases cytoplasmic mRNA levels, established BCLAF1 as a regulator of mRNA subcellular distribution beyond its transcription factor role.","evidence":"Live-cell imaging at reporter loci, nuclear/cytoplasmic fractionation, RT-PCR after siRNA knockdown","pmids":["23778535"],"confidence":"Medium","gaps":["Whether BCLAF1 directly binds mRNA or acts indirectly through EJC not resolved","Specificity of affected transcripts not determined genome-wide"]},{"year":2014,"claim":"The demonstration that SRSF10 drives inclusion of BCLAF1 exon 5a to generate an oncogenic isoform in colorectal cancer showed that BCLAF1 function is itself regulated by alternative splicing, adding isoform-level complexity.","evidence":"RT-PCR splicing assays, knockdown/overexpression, tumor growth assays in colon cancer cells and patient samples","pmids":["25091051"],"confidence":"High","gaps":["Functional domain encoded by exon 5a not biochemically characterized","Whether other BCLAF1 isoforms have distinct functions unknown"]},{"year":2016,"claim":"Identifying BCLAF1 as a bridge between NF-κB and C/EBPβ to drive the senescence-associated secretory phenotype (IL-6/IL-8) established a new cell-fate role for BCLAF1 in therapy-induced senescence.","evidence":"ChIP, Co-IP, reporter assays, IL-6/IL-8 ELISA, xenograft model after doxorubicin treatment","pmids":["26794446"],"confidence":"High","gaps":["Whether BCLAF1 is required for all SASP components or only IL-6/IL-8 unclear","Relationship between BCLAF1's senescence and apoptosis roles not delineated"]},{"year":2017,"claim":"Multiple studies converged to show BCLAF1 functions as a selective mRNA splicing/export factor for DDR transcripts (including ATM), and as a cofactor for type I interferon signaling through direct STAT2 interaction, broadening its role to RNA processing and innate immunity.","evidence":"RNA-seq splicing analysis, nuclear export assays, DNA damage sensitivity for DDR role; CRISPR/siRNA, Co-IP, ChIP at ISRE elements for IFN role; viral exploitation by alphaherpesvirus US3","pmids":["29112714","30682178","28895891"],"confidence":"High","gaps":["Full catalog of BCLAF1-dependent splicing events not defined","Mechanism by which BCLAF1 selects specific transcripts for splicing regulation unknown","Whether BCLAF1's IFN role extends to type II/III interferons not tested"]},{"year":2018,"claim":"Discovery of a HIF-1α/BCLAF1 positive feedback loop under hypoxia — BCLAF1 transcribes HIF1A via its bZIP domain while HIF-1α reciprocally upregulates BCLAF1 — and identification of BCLAF1 as a CRY2-dependent mRNA stabilizer in myogenesis, demonstrated dual transcriptional and post-transcriptional functions in distinct biological contexts.","evidence":"ChIP, reporter assays with bZIP mutants, xenografts for hypoxia; Co-IP, RNA stability assays, Cry2 KO mice for myogenesis","pmids":["30367150","29466738"],"confidence":"High","gaps":["Direct RNA-binding domains/motifs of BCLAF1 for mRNA stabilization not mapped","Whether HIF-1α feedback operates in non-tumor contexts undetermined"]},{"year":2019,"claim":"Structural and functional advances revealed that BCLAF1 forms a transcription factor complex with SPIC to displace PU.1 genome-wide during B-cell development, and that phosphorylated BCLAF1 binds the PP1/SDS22 phosphatase complex, identifying post-translational regulation of BCLAF1.","evidence":"ChIP-seq, Co-IP, genetic epistasis in pre-B cells for SPIC complex; X-ray crystallography of SDS22, biochemical binding for PP1","pmids":["31644907","30661852"],"confidence":"High","gaps":["Which phosphorylation sites on BCLAF1 are regulated by PP1/SDS22 undefined","Whether SPIC/BCLAF1 complex operates outside B cells unclear"]},{"year":2020,"claim":"CRISPR knockout confirmed BCLAF1 stabilizes HIF-1α protein in the nucleus during sustained hypoxia, validating the positive feedback loop with genetic loss-of-function and in vivo xenograft evidence.","evidence":"CRISPR knockout, Co-IP, protein stability assays, xenograft tumor growth measurement","pmids":["32029898"],"confidence":"High","gaps":["Structural mechanism of HIF-1α stabilization by BCLAF1 unresolved","Whether BCLAF1 protects HIF-1α from VHL-mediated or VHL-independent degradation not distinguished"]},{"year":2021,"claim":"Two studies resolved context-dependent pro- vs anti-apoptotic roles: BCLAF1 promotes cardiomyocyte apoptosis after ischemia-reperfusion (sequestered by lncCIRBIL), while in TNF signaling it prevents apoptosis by activating CFLAR/c-FLIP transcription via NF-κB p50, explaining the long-standing paradox of its dual roles.","evidence":"Transgenic/KO mouse epistasis for cardiac I/R; Co-IP, ChIP at CFLAR promoter, TNF-induced apoptosis assays, in vivo siRNA for TNF pathway","pmids":["33483496","34693625"],"confidence":"High","gaps":["What determines pro- vs anti-apoptotic output in a given cell type not defined","Post-translational modifications dictating context-dependent function not mapped systematically"]},{"year":2022,"claim":"Identification of BCLAF1 as a competitive inhibitor of SPOP-mediated PD-L1 ubiquitination through a defined SBC motif, and as a TET2 partner regulating promoter hydroxymethylation, expanded BCLAF1 into immune checkpoint regulation and epigenetic control.","evidence":"Site-directed mutagenesis of SBC motif, ubiquitination competition assay, T-cell cytotoxicity for SPOP/PD-L1; LC-MS/MS, PLA, ChIP-qPCR, glucosylated hydroxymethyl-qPCR for TET2","pmids":["38340178","35660018"],"confidence":"High","gaps":["In vivo relevance of BCLAF1-SPOP axis for anti-tumor immunity not tested","Genome-wide scope of TET2-BCLAF1 hydroxymethylation targets unknown"]},{"year":2023,"claim":"Cross-linking mass spectrometry defined the BCLAF1-THRAP3-ERH (TEB) complex topology, mapping interaction surfaces to ordered regions within these largely disordered proteins and suggesting a stable ternary complex as the functional unit for RNA processing.","evidence":"XL-MS with DSSO crosslinker after immunoprecipitation of endogenous proteins","pmids":["35865489"],"confidence":"Medium","gaps":["Functional validation of TEB complex as a unit is absent","No reconstitution or structural model beyond crosslink restraints","Stoichiometry and dynamics of the complex unknown"]},{"year":2024,"claim":"Multiple studies expanded the BCLAF1 interaction network: BACH1/BRCA1-dependent recruitment to DNA damage sites for homologous recombination, YTHDF2 antagonism to stabilize m6A-modified mRNAs, LAMTOR2-regulated nuclear translocation, and MED23 partnership for NUPR1 transcription, each linking BCLAF1 to additional pathways.","evidence":"Tandem affinity purification and HR reporter for BACH1; MS, Co-IP, GST pull-down, MeRIP-seq for YTHDF2; Co-IP, fractionation, OA mouse model for LAMTOR2; Co-IP, PLA, ChIP for MED23","pmids":["35930920","38636894","39990659","39366174"],"confidence":"Medium","gaps":["Mechanism by which BCLAF1 participates in HR downstream of RAD51 foci undefined","Whether BCLAF1-YTHDF2 interaction is direct and stoichiometric needs further validation","Selectivity of LAMTOR2 regulation of BCLAF1 nuclear entry unclear"]},{"year":2025,"claim":"Recent work revealed that nuclear p85β recruits BCLAF1 into an autoregulatory transcriptional loop with TRIM28/ZNF263, BCKDK phosphorylates BCLAF1 at S285 to promote MYC transcription and glycolysis, and BCLAF1 activates POLR2A through dual transcriptional and splicing mechanisms — collectively demonstrating that BCLAF1 is itself a hub for multiple upstream kinase and cofactor inputs.","evidence":"ChIP-seq/proteomics for p85β; Co-IP, S285 phosphorylation, ChIP at MYC promoter for BCKDK; ATAC-seq, CUT&Tag, RIP for POLR2A regulation","pmids":["40016211","40442441","40220379"],"confidence":"Medium","gaps":["Whether S285 phosphorylation by BCKDK occurs in non-cancer contexts not known","Complete phosphoproteome map of BCLAF1 lacking","Whether POLR2A regulation is a direct or indirect consequence of BCLAF1's general splicing role unclear"]},{"year":null,"claim":"A comprehensive structural model of full-length BCLAF1, the rules governing its context-dependent switch between pro- and anti-apoptotic outputs, and the relative contributions of its transcriptional versus RNA-processing functions in each physiological setting remain to be established.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of full-length BCLAF1 or its key domains beyond bZIP homology","Systematic mapping of post-translational modifications and their functional consequences incomplete","No unified model explaining how one protein integrates transcription, splicing, and mRNA stability in a context-dependent manner"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,9,12,14,18,28,31]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,11,12]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[7,10,13,29,33]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[19,24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,2,7,11,14,16,17,20,28]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[7,14,15,28]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[5,25]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,9,12,14,18,28,31,33]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[7,8,10,29,33]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[5,10,25]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,2,5,17,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,11,19]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[9,12,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,14]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,20]}],"complexes":["BCLAF1-THRAP3-ERH (TEB) complex","SPIC-BCLAF1 transcription factor complex","TET2-BCLAF1 complex","p85β-BCLAF1-TRIM28-ZNF263 complex"],"partners":["THRAP3","SPIC","SPOP","HIF1A","NFKB1","STAT2","BACH1","CRY2"],"other_free_text":[]},"mechanistic_narrative":"BCLAF1 is a multifunctional nuclear protein that integrates transcriptional regulation, mRNA splicing, and mRNA stability control across diverse cellular processes including apoptosis, the DNA damage response, immune signaling, hypoxic adaptation, and developmental programs. Through its bZIP-like domain, BCLAF1 activates or represses transcription at specific promoters — driving TP53 expression with PKCδ after genotoxic stress [PMID:17938203], CFLAR (c-FLIP) expression with NF-κB p50 to restrain TNF-induced apoptosis [PMID:34693625], HIF1A in a positive feedback loop under hypoxia [PMID:30367150, PMID:32029898], and IL-6/IL-8 with C/EBPβ during therapy-induced senescence [PMID:26794446] — while also forming transcription factor complexes with SPIC to regulate B-cell development [PMID:31644907], with TET2 to control promoter hydroxymethylation [PMID:35660018], and with p85β/TRIM28/ZNF263 in an autoregulatory circuit [PMID:40016211]. BCLAF1 additionally associates with spliceosome components and the THRAP3/ERH complex to regulate alternative splicing and nuclear export of transcripts critical for the DNA damage response, mitotic fidelity, and metabolic homeostasis, including ATM kinase and ATF4 mRNAs [PMID:29112714, PMID:35865489], and stabilizes specific mRNAs such as cyclin D1 downstream of the circadian regulator CRY2 [PMID:29466738]. Knockout mice reveal requirements for lung smooth muscle morphogenesis and peripheral T-cell homeostasis independent of a simple proapoptotic role, while BCLAF1 also functions as a viral restriction factor neutralized by HCMV and alphaherpesviruses [PMID:19008920, PMID:22645331, PMID:30682178]."},"prefetch_data":{"uniprot":{"accession":"Q9NYF8","full_name":"Bcl-2-associated transcription factor 1","aliases":["BCLAF1 and THRAP3 family member 1"],"length_aa":920,"mass_kda":106.1,"function":"Death-promoting transcriptional repressor. May be involved in cyclin-D1/CCND1 mRNA stability through the SNARP complex which associates with both the 3'end of the CCND1 gene and its mRNA","subcellular_location":"Cytoplasm; Nucleus; Nucleus speckle; Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/Q9NYF8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BCLAF1","classification":"Common Essential","n_dependent_lines":1028,"n_total_lines":1208,"dependency_fraction":0.8509933774834437},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PRPF4B","stoichiometry":4.0},{"gene":"SSRP1","stoichiometry":4.0},{"gene":"TOP1","stoichiometry":4.0},{"gene":"CD2BP2","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"DDX21","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"RBM39","stoichiometry":0.2},{"gene":"RNF40","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BCLAF1","total_profiled":1310},"omim":[{"mim_id":"616731","title":"NIMA-RELATED KINASE 5; NEK5","url":"https://www.omim.org/entry/616731"},{"mim_id":"616453","title":"ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 13; ZC3H13","url":"https://www.omim.org/entry/616453"},{"mim_id":"616447","title":"VIR-LIKE M6A METHYLTRANSFERASE-ASSOCIATED PROTEIN; VIRMA","url":"https://www.omim.org/entry/616447"},{"mim_id":"612588","title":"BCL2-ASSOCIATED TRANSCRIPTION FACTOR 1; BCLAF1","url":"https://www.omim.org/entry/612588"},{"mim_id":"606872","title":"CAS-BR-M MURINE ECTOPIC RETROVIRAL TRANSFORMING SEQUENCE LIKE-1; CBLL1","url":"https://www.omim.org/entry/606872"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nuclear speckles","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":127.3}],"url":"https://www.proteinatlas.org/search/BCLAF1"},"hgnc":{"alias_symbol":["KIAA0164","BTF"],"prev_symbol":[]},"alphafold":{"accession":"Q9NYF8","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYF8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYF8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYF8-F1-predicted_aligned_error_v6.png","plddt_mean":46.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCLAF1","jax_strain_url":"https://www.jax.org/strain/search?query=BCLAF1"},"sequence":{"accession":"Q9NYF8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NYF8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NYF8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYF8"}},"corpus_meta":[{"pmid":"10330179","id":"PMC_10330179","title":"Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10330179","citation_count":179,"is_preprint":false},{"pmid":"25091051","id":"PMC_25091051","title":"BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25091051","citation_count":150,"is_preprint":false},{"pmid":"15009215","id":"PMC_15009215","title":"Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy.","date":"2004","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15009215","citation_count":125,"is_preprint":false},{"pmid":"17938203","id":"PMC_17938203","title":"Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17938203","citation_count":95,"is_preprint":false},{"pmid":"30367150","id":"PMC_30367150","title":"Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30367150","citation_count":93,"is_preprint":false},{"pmid":"29112714","id":"PMC_29112714","title":"The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29112714","citation_count":86,"is_preprint":false},{"pmid":"21454709","id":"PMC_21454709","title":"The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454709","citation_count":82,"is_preprint":false},{"pmid":"22833098","id":"PMC_22833098","title":"BCLAF1 is a radiation-induced H2AX-interacting partner involved in γH2AX-mediated regulation of apoptosis and DNA repair.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22833098","citation_count":81,"is_preprint":false},{"pmid":"19008920","id":"PMC_19008920","title":"Essential role for Bclaf1 in lung development and immune system function.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19008920","citation_count":71,"is_preprint":false},{"pmid":"28216661","id":"PMC_28216661","title":"miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28216661","citation_count":66,"is_preprint":false},{"pmid":"22645331","id":"PMC_22645331","title":"BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22645331","citation_count":66,"is_preprint":false},{"pmid":"26794446","id":"PMC_26794446","title":"Bclaf1 is an important NF-κB signaling transducer and C/EBPβ regulator in DNA damage-induced senescence.","date":"2016","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26794446","citation_count":58,"is_preprint":false},{"pmid":"35882275","id":"PMC_35882275","title":"Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35882275","citation_count":57,"is_preprint":false},{"pmid":"20661537","id":"PMC_20661537","title":"In search of a function for BCLAF1.","date":"2010","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/20661537","citation_count":56,"is_preprint":false},{"pmid":"29466738","id":"PMC_29466738","title":"Cry2 Is Critical for Circadian Regulation of Myogenic Differentiation by Bclaf1-Mediated mRNA Stabilization of Cyclin D1 and Tmem176b.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29466738","citation_count":53,"is_preprint":false},{"pmid":"33483496","id":"PMC_33483496","title":"The long noncoding RNA lncCIRBIL disrupts the nuclear translocation of Bclaf1 alleviating cardiac ischemia-reperfusion injury.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33483496","citation_count":52,"is_preprint":false},{"pmid":"30682178","id":"PMC_30682178","title":"Bclaf1 critically regulates the type I interferon response and is degraded by alphaherpesvirus US3.","date":"2019","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/30682178","citation_count":51,"is_preprint":false},{"pmid":"26676636","id":"PMC_26676636","title":"Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26676636","citation_count":49,"is_preprint":false},{"pmid":"31870774","id":"PMC_31870774","title":"BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31870774","citation_count":45,"is_preprint":false},{"pmid":"19705920","id":"PMC_19705920","title":"The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells.","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19705920","citation_count":45,"is_preprint":false},{"pmid":"33363466","id":"PMC_33363466","title":"Ginsenoside Compound K Regulates HIF-1α-Mediated Glycolysis Through Bclaf1 to Inhibit the Proliferation of Human Liver Cancer Cells.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33363466","citation_count":37,"is_preprint":false},{"pmid":"36522479","id":"PMC_36522479","title":"Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36522479","citation_count":36,"is_preprint":false},{"pmid":"34992690","id":"PMC_34992690","title":"Function of BCLAF1 in human disease.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34992690","citation_count":35,"is_preprint":false},{"pmid":"33188158","id":"PMC_33188158","title":"LncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p/BCLAF1 axis as a ceRNA.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33188158","citation_count":33,"is_preprint":false},{"pmid":"38340178","id":"PMC_38340178","title":"BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38340178","citation_count":28,"is_preprint":false},{"pmid":"32029898","id":"PMC_32029898","title":"Bclaf1 is a direct target of HIF-1 and critically regulates the stability of HIF-1α under hypoxia.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32029898","citation_count":23,"is_preprint":false},{"pmid":"35321563","id":"PMC_35321563","title":"Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis.","date":"2022","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35321563","citation_count":22,"is_preprint":false},{"pmid":"23778535","id":"PMC_23778535","title":"Btf and TRAP150 have distinct roles in regulating subcellular mRNA distribution.","date":"2013","source":"Nucleus (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23778535","citation_count":21,"is_preprint":false},{"pmid":"32968449","id":"PMC_32968449","title":"BCLAF1 induces cisplatin resistance in lung cancer cells.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32968449","citation_count":20,"is_preprint":false},{"pmid":"38805063","id":"PMC_38805063","title":"CircZFR promotes colorectal cancer progression via stabilizing BCLAF1 and regulating the miR-3127-5p/RTKN2 axis.","date":"2024","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38805063","citation_count":19,"is_preprint":false},{"pmid":"29969367","id":"PMC_29969367","title":"Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29969367","citation_count":19,"is_preprint":false},{"pmid":"31644907","id":"PMC_31644907","title":"RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31644907","citation_count":17,"is_preprint":false},{"pmid":"30661852","id":"PMC_30661852","title":"Structure-Guided Exploration of SDS22 Interactions with Protein Phosphatase PP1 and the Splicing Factor BCLAF1.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30661852","citation_count":16,"is_preprint":false},{"pmid":"34693625","id":"PMC_34693625","title":"Bclaf1 regulates c-FLIP expression and protects cells from TNF-induced apoptosis and tissue injury.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/34693625","citation_count":16,"is_preprint":false},{"pmid":"38878918","id":"PMC_38878918","title":"Transfer of miR-877-3p via extracellular vesicles derived from dental pulp stem cells attenuates neuronal apoptosis and facilitates early neurological functional recovery after cerebral ischemia-reperfusion injury through the Bclaf1/P53 signaling pathway.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/38878918","citation_count":15,"is_preprint":false},{"pmid":"35660018","id":"PMC_35660018","title":"TET2-BCLAF1 transcription repression complex epigenetically regulates the expression of colorectal cancer gene Ascl2 via methylation of its promoter.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35660018","citation_count":15,"is_preprint":false},{"pmid":"34251713","id":"PMC_34251713","title":"Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34251713","citation_count":15,"is_preprint":false},{"pmid":"34088200","id":"PMC_34088200","title":"Evaluation of NOx removal from flue gas and Fe(II)EDTA regeneration using a novel BTF-ABR integrated system.","date":"2021","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/34088200","citation_count":13,"is_preprint":false},{"pmid":"38636894","id":"PMC_38636894","title":"BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38636894","citation_count":12,"is_preprint":false},{"pmid":"35930920","id":"PMC_35930920","title":"BCLAF1, a functional partner of BACH1, participates in DNA damage response.","date":"2022","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/35930920","citation_count":7,"is_preprint":false},{"pmid":"11790742","id":"PMC_11790742","title":"Isolation and characterization of BTF-37: chromosomal DNA captured from Bacteroides fragilis that confers self-transferability and expresses a pilus-like structure in Bacteroides spp. and Escherichia coli.","date":"2002","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/11790742","citation_count":7,"is_preprint":false},{"pmid":"37906282","id":"PMC_37906282","title":"BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex.","date":"2023","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/37906282","citation_count":6,"is_preprint":false},{"pmid":"28895891","id":"PMC_28895891","title":"Alignment of Mitotic Chromosomes in Human Cells Involves SR-Like Splicing Factors Btf and TRAP150.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28895891","citation_count":6,"is_preprint":false},{"pmid":"38467765","id":"PMC_38467765","title":"Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway.","date":"2024","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38467765","citation_count":6,"is_preprint":false},{"pmid":"40442441","id":"PMC_40442441","title":"Targeting the BCKDK/BCLAF1/MYC/HK2 axis to alter aerobic glycolysis and overcome Trametinib resistance in lung cancer.","date":"2025","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/40442441","citation_count":5,"is_preprint":false},{"pmid":"17720457","id":"PMC_17720457","title":"Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37.","date":"2007","source":"Research in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17720457","citation_count":4,"is_preprint":false},{"pmid":"40435510","id":"PMC_40435510","title":"BCLAF1 restrains stress responses in hematopoietic stem cells to support expansion and repopulation.","date":"2025","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/40435510","citation_count":3,"is_preprint":false},{"pmid":"35865489","id":"PMC_35865489","title":"Identifying and characterising Thrap3, Bclaf1 and Erh interactions using cross-linking mass spectrometry.","date":"2023","source":"Wellcome open research","url":"https://pubmed.ncbi.nlm.nih.gov/35865489","citation_count":3,"is_preprint":false},{"pmid":"39891142","id":"PMC_39891142","title":"Ionizing radiation-induced disruption of Rela-Bclaf1-spliceosome regulatory axis in primary spermatocytes causing spermatogenesis dysfunction.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39891142","citation_count":3,"is_preprint":false},{"pmid":"40220379","id":"PMC_40220379","title":"Bclaf1 mediates super-enhancer-driven activation of POLR2A to enhance chromatin accessibility in nitrosamine-induced esophageal carcinogenesis.","date":"2025","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/40220379","citation_count":3,"is_preprint":false},{"pmid":"34512018","id":"PMC_34512018","title":"Role of Bclaf1 in Promoting Adrenocortical Carcinoma Proliferation: A Study Combining the Use of Bioinformatics and Molecular Events.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/34512018","citation_count":3,"is_preprint":false},{"pmid":"38198022","id":"PMC_38198022","title":"BCLAF1 is Expressed as a Potential Anti-oncogene in Bile Duct Cancer.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38198022","citation_count":3,"is_preprint":false},{"pmid":"38573525","id":"PMC_38573525","title":"Pan-Cancer Analysis Identifies BCLAF1 as a Potential Biomarker for Renal Cell Carcinoma.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38573525","citation_count":2,"is_preprint":false},{"pmid":"34490482","id":"PMC_34490482","title":"New insights from Whole Genome Sequencing: BCLAF1 deletion as a structural variant that predisposes cells towards cellular transformation.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34490482","citation_count":2,"is_preprint":false},{"pmid":"39366174","id":"PMC_39366174","title":"MED23 depletion induces premature senescence in NSCLC cells by interacting with BCLAF1 and then suppressing NUPR1 expression.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39366174","citation_count":1,"is_preprint":false},{"pmid":"39444606","id":"PMC_39444606","title":"Sorbaria sorbifolia flavonoid derivative induces mitochondrial apoptosis in human hepatoma cells through Bclaf1.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39444606","citation_count":1,"is_preprint":false},{"pmid":"39990659","id":"PMC_39990659","title":"BCLAF1 Regulates Osteoarthritic Cartilage Degradation Through Interaction with LAMTOR2.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39990659","citation_count":1,"is_preprint":false},{"pmid":"23243848","id":"PMC_23243848","title":"[Characteristics of biofilm phase during the long-term degradation of a toluene-contaminated gas stream using BTF].","date":"2012","source":"Huan jing ke xue= Huanjing kexue","url":"https://pubmed.ncbi.nlm.nih.gov/23243848","citation_count":1,"is_preprint":false},{"pmid":"40016211","id":"PMC_40016211","title":"p85β acts as a transcription cofactor and cooperates with BCLAF1 in the nucleus.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40016211","citation_count":0,"is_preprint":false},{"pmid":"40635045","id":"PMC_40635045","title":"A novel MIR100HG transcript enhances tumorigenesis by inducing BCLAF1-mediated alternative splicing in colorectal cancer.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/40635045","citation_count":0,"is_preprint":false},{"pmid":"36775032","id":"PMC_36775032","title":"Effects of various COD/NO ratios on NOx removal performance and microbial communities in a BTF-ABR integrated system.","date":"2023","source":"Chemosphere","url":"https://pubmed.ncbi.nlm.nih.gov/36775032","citation_count":0,"is_preprint":false},{"pmid":"41872140","id":"PMC_41872140","title":"Dynamic epigenetic regulation of BCLAF1 splicing in acute myeloid leukemia.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41872140","citation_count":0,"is_preprint":false},{"pmid":"41648520","id":"PMC_41648520","title":"BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41648520","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.04.636487","title":"Bclaf1 biomolecular condensates protect nuclear PTK2 from ubiquitin-proteasome system promoting cardiomyocyte survival during oxidative stress","date":"2025-02-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.04.636487","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.16.649147","title":"A microRNA CRISPR screen reveals miR-483-3p as an apoptotic regulator in prostate cancer","date":"2025-04-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.16.649147","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.11.669643","title":"Structure and function of a fungal AB toxin-like chimerolectin involved in anti-nematode defense","date":"2025-08-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.11.669643","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.29.620871","title":"Single-Cell Atlas of AML Reveals Age-Related Gene Regulatory Networks in t(8;21) AML","date":"2024-11-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.29.620871","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.07.606975","title":"Research on the Mechanism of Lphn1 Knockout in Inhibiting Colorectal Cancer","date":"2024-08-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.07.606975","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.20.24315403","title":"Improved Sensitivity For Detection Of Clinical Deterioration When Diagnostic Pathology And Patient Trends Are Included In Machine Learning Models","date":"2024-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.20.24315403","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35482,"output_tokens":8655,"usd":0.118136},"stage2":{"model":"claude-opus-4-6","input_tokens":12519,"output_tokens":5442,"usd":0.297967},"total_usd":0.416103,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"BCLAF1 (Btf) was identified as a novel protein that interacts with the antiapoptotic proteins E1B 19K, Bcl-2, and Bcl-xL (but not proapoptotic Bax) via yeast two-hybrid screening. Btf contains homology to bZIP and Myb DNA-binding domains, binds DNA in vitro, and represses transcription in reporter assays. E1B 19K, Bcl-2, and Bcl-xL sequester Btf in the cytoplasm and block its transcriptional repression activity. Sustained overexpression of Btf in HeLa cells induced apoptosis, which was inhibited by E1B 19K.\",\n      \"method\": \"Yeast two-hybrid, in vitro DNA binding, reporter transcription assays, overexpression/apoptosis assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original discovery with multiple orthogonal methods; foundational highly-cited paper\",\n      \"pmids\": [\"10330179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Emerin (a nuclear membrane protein mutated in Emery-Dreifuss muscular dystrophy) directly binds BCLAF1/Btf with KD ~100 nM. The emerin disease-causing missense mutation S54F selectively disrupts binding to Btf without affecting binding to lamin A or GCL. Upon Fas-induced apoptosis, Btf redistributes from dot-like nuclear structures to a zone near the nuclear envelope, suggesting apoptotic regulation of Btf localization.\",\n      \"method\": \"Yeast two-hybrid, biochemical binding/affinity measurement, alanine-substitution mutagenesis, indirect immunofluorescence\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — binding affinity measured, mutagenesis, localization studies; highly cited\",\n      \"pmids\": [\"15009215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKCδ interacts with BCLAF1/Btf upon DNA damage and co-occupies the TP53 core promoter element (CPE-TP53), driving TP53 transcription. Inhibition of PKCδ activity reduces Btf affinity for CPE-TP53, lowering TP53 mRNA and protein levels. RNAi-mediated disruption of Btf-mediated TP53 transcription suppresses TP53-dependent apoptosis after genotoxic stress.\",\n      \"method\": \"Reporter assays, Co-IP, ChIP, RNAi knockdown, RT-PCR, Western blot\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, Co-IP, reporter, RNAi) in single lab; strong mechanistic detail\",\n      \"pmids\": [\"17938203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Bclaf1 knockout mice show defects in lung saccular-stage smooth muscle organization and peripheral T-cell homeostasis, but not thymocyte development. Bclaf1-deficient cells do not show defects in apoptosis after various stimuli, indicating Bclaf1 is required for developmental processes independent of its postulated proapoptotic role.\",\n      \"method\": \"Targeted gene knockout in mice, histology, FACS analysis of immune cells\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse with defined cellular phenotypes across multiple tissues\",\n      \"pmids\": [\"19008920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sirt1 suppresses BCLAF1 transcription by deacetylating histone H3 lysine 56 (H3K56) at the bclaf1 promoter. Upon TCR/CD28 stimulation, Sirt1 is recruited to the bclaf1 promoter by forming a complex with p300 and NF-κB subunit Rel-A; only p300 (not GCN5) specifically acetylates H3K56 at this promoter. Knockdown of Bclaf1 suppresses hyperactivation of Sirt1-null T cells, placing Bclaf1 downstream of Sirt1 in T cell activation.\",\n      \"method\": \"ChIP, siRNA knockdown, H3K56 acetylation assay, IL-2 ELISA, proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with multiple controls, epistasis via knockdown, clear pathway placement\",\n      \"pmids\": [\"21454709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCLAF1 associates with γH2AX in a radiation dose-dependent manner. Under high-dose ionizing radiation, BCLAF1 promotes apoptosis by disrupting p21-mediated inhibition of caspase/cyclin E-dependent mitochondrial pathways and co-localizes with γH2AX foci while stabilizing the Ku70/DNA-PKcs complex to facilitate NHEJ-based DSB repair in surviving cells. In tumor cells, BCLAF1 is suppressed, leading to anti-apoptotic Ku70-Bax complexes and defective NHEJ repair.\",\n      \"method\": \"Mass spectrometry-based identification, Co-IP, immunofluorescence colocalization, siRNA knockdown, apoptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS identification followed by Co-IP, colocalization, functional knockdown with defined phenotypes\",\n      \"pmids\": [\"22833098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Human cytomegalovirus uses two independent mechanisms to neutralize BCLAF1 as a restriction factor: (1) virion-delivered pp71 and UL35 proteins direct proteasomal degradation of BCLAF1 immediately post-infection; (2) virus-encoded miR-UL112-1 downregulates BCLAF1 at late infection stages. In the absence of BCLAF1 neutralization, viral gene expression and replication are inhibited.\",\n      \"method\": \"Viral infection assays, siRNA knockdown, proteasome inhibitor treatment, miRNA functional assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two distinct mechanistic pathways demonstrated with multiple methods\",\n      \"pmids\": [\"22645331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Btf (BCLAF1) and TRAP150 both localize at active transcription loci in a RNA polymerase II-dependent manner and overlap with the exon junction complex (EJC) protein Magoh. Btf depletion (but not TRAP150 depletion) causes increased cytoplasmic levels of β-tropomyosin reporter transcripts and global increase of endogenous polyadenylated RNA in the cytoplasm, indicating a distinct role for Btf in regulating subcellular mRNA distribution.\",\n      \"method\": \"Live-cell imaging at reporter loci, siRNA knockdown, nuclear/cytoplasmic fractionation, RT-PCR\",\n      \"journal\": \"Nucleus (Austin, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional fractionation consequence, single lab\",\n      \"pmids\": [\"23778535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The splicing factor SRSF10 stimulates inclusion of BCLAF1 alternative exon 5a, generating a distinct protein isoform. The BCLAF1 isoform resulting from exon 5a inclusion promotes growth and tumorigenic potential of colon cancer cells, while its knockdown inhibits these effects. SRSF10 upregulation in colorectal cancer parallels increased exon 5a inclusion, linking SRSF10-regulated splicing to BCLAF1 oncogenic isoform production.\",\n      \"method\": \"RT-PCR splicing assays, siRNA knockdown, overexpression, tumor growth assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — splicing mechanism defined, functional consequence validated, replicated in clinical samples; highly cited\",\n      \"pmids\": [\"25091051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Bclaf1 is upregulated through the ATM/Nemo/NF-κB pathway during doxorubicin-induced senescence and is a direct transcriptional target of p65 and c-Rel. Bclaf1 physically interacts with the leucine zipper region of C/EBPβ and together they upregulate IL-6 and IL-8 transcription to establish the senescence-associated secretory phenotype (SASP). Bclaf1 is thus an NF-κB-to-C/EBPβ transducer in therapy-induced senescence.\",\n      \"method\": \"ChIP, Co-IP, siRNA knockdown, reporter assays, IL-6/IL-8 ELISA, xenograft model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction, ChIP, and functional pathway placement with multiple methods\",\n      \"pmids\": [\"26794446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"THRAP3 and BCLAF1 promote the DNA damage response by selectively regulating mRNA splicing and nuclear export of key DDR transcripts, including ATM kinase mRNA. Loss of either protein leads to sensitivity to DNA damaging agents, defective DNA repair, and genomic instability. Cancer-associated mutations in THRAP3 deregulate THRAP3/BCLAF1-controlled transcript processing.\",\n      \"method\": \"siRNA knockdown, RNA-seq splicing analysis, nuclear export assays, DNA damage sensitivity assays, comet assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, defined mechanism of selective mRNA processing\",\n      \"pmids\": [\"29112714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Bclaf1 is required for type I interferon (IFNα) signaling: Bclaf1 maintains efficient STAT1 and STAT2 phosphorylation in response to IFNα, directly interacts with ISRE elements and STAT2 to facilitate ISGF3 binding for gene transcription. Alphaherpesvirus US3 protein degrades Bclaf1 to impair IFNα-mediated antiviral defense.\",\n      \"method\": \"CRISPR/siRNA knockdown, Co-IP, ChIP, STAT phosphorylation assays, viral replication assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction with STAT2/ISRE defined, multiple functional assays, viral mechanism characterized\",\n      \"pmids\": [\"30682178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Bclaf1 promotes HIF1A transcription via its bZIP domain in hepatocellular carcinoma cells under hypoxia, leading to increased downstream VEGFA, TGFB, and EPO expression and angiogenesis. Conversely, HIF-1α increases Bclaf1 levels in hypoxia, forming a positive feedback loop. Bclaf1 knockdown in xenograft tumors reduces HIF-1α levels and microvessel density.\",\n      \"method\": \"shRNA knockdown, reporter assays with bZIP domain mutants, Western blot, xenograft experiments, ChIP\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-level mechanistic detail, in vivo validation, positive feedback loop defined\",\n      \"pmids\": [\"30367150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cry2 interacts specifically with Bclaf1 (not Cry1), and this interaction stabilizes mRNAs encoding cyclin D1 and Tmem176b in myoblasts. Loss of Cry2 or Bclaf1 knockdown recapitulates the same phenotype: premature cell cycle exit and inefficient myotube fusion. Bclaf1 thus acts as a post-transcriptional mRNA stabilizer downstream of the circadian regulator Cry2.\",\n      \"method\": \"Co-IP, RNA stability assays, siRNA knockdown, cell fusion assays, Cry2 KO mice, muscle regeneration assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction, mRNA stabilization mechanism, phenotypic rescue, in vivo validation\",\n      \"pmids\": [\"29466738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A SPIC/BCLAF1 transcription factor complex is activated by RAG-generated DNA double-strand breaks in pre-B cells. SPIC recruits BCLAF1 to gene-regulatory elements, and the complex displaces PU.1 from chromatin genome-wide and suppresses SYK tyrosine kinase expression, enforcing the transition from large to small pre-B cells.\",\n      \"method\": \"ChIP-seq, Co-IP, genetic loss-of-function, gene expression profiling, B cell development assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq, Co-IP, and genetic epistasis defining pathway\",\n      \"pmids\": [\"31644907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of SDS22 shows its leucine-rich repeat domain adopts a banana-shaped fold with a large basic surface patch that enables binding of a phosphorylated form of BCLAF1. Biochemical studies show SDS22 acts as a 'third' subunit of multiple PP1 holoenzymes and recruits additional interactors such as phosphorylated BCLAF1.\",\n      \"method\": \"X-ray crystallography, biochemical binding studies\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with biochemical validation of BCLAF1-SDS22 interaction\",\n      \"pmids\": [\"30661852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Bclaf1 is a direct transcriptional target of HIF-1 and is upregulated during hypoxia. Bclaf1 binds HIF-1α in the nucleus, and this interaction stabilizes HIF-1α protein during long-term hypoxia, protecting it from degradation. Bclaf1 knockout cells show reduced HIF-1α stability and impaired HIF-1 target gene induction; Bclaf1 knockout xenografts show reduced tumor growth with decreased HIF-1α.\",\n      \"method\": \"ChIP, Co-IP, protein stability assays, CRISPR knockout, xenograft experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct nuclear interaction defined, CRISPR KO, in vivo validation\",\n      \"pmids\": [\"32029898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The long noncoding RNA lncCIRBIL directly binds to Bclaf1 and inhibits its nuclear translocation. Cardiomyocyte-specific transgenic overexpression of lncCIRBIL reduces cardiac infarct area after ischemia-reperfusion (I/R) injury, while Bclaf1 transgenic overexpression worsens I/R injury. Partial Bclaf1 knockout abrogates the detrimental effects of lncCIRBIL knockout, placing Bclaf1 downstream of lncCIRBIL in cardiac I/R injury.\",\n      \"method\": \"RNA-protein binding assay, nuclear fractionation, transgenic mouse models, Bclaf1 KO, infarct area measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-protein interaction, genetic epistasis via multiple transgenic models, in vivo functional readout\",\n      \"pmids\": [\"33483496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Bclaf1 exerts anti-apoptotic function in TNF signaling by promoting transcription of CFLAR (c-FLIP), a caspase-8 antagonist. Bclaf1 binds the p50 subunit of NF-κB, and this interaction is required for Bclaf1 to stimulate CFLAR transcription. Bclaf1 depletion sensitizes cells to TNF-induced apoptosis but not necroptosis, and in mice, siRNA-mediated Bclaf1 depletion aggravates TNF-induced intestinal injury.\",\n      \"method\": \"Co-IP, ChIP, siRNA knockdown, apoptosis/necroptosis assays, in vivo siRNA administration\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction with NF-κB p50, ChIP at CFLAR promoter, pathway placement, in vivo validation\",\n      \"pmids\": [\"34693625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCLAF1 interacts with SPOP (an E3 ligase adaptor) through an SPOP-binding consensus (SBC) motif on BCLAF1, competitively inhibiting SPOP-mediated ubiquitination and degradation of PD-L1. Mutation of the BCLAF1-SBC motif disrupts BCLAF1-SPOP interaction and abolishes BCLAF1-mediated PD-L1 stabilization. BCLAF1 depletion reduces PD-L1 expression and promotes T cell-mediated cytotoxicity.\",\n      \"method\": \"Co-IP, site-directed mutagenesis (SBC motif), ubiquitination assay, PD-L1 stability assay, T cell co-culture cytotoxicity\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic mutagenesis of interaction motif, direct ubiquitination competition assay, functional readout\",\n      \"pmids\": [\"38340178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TET2 and BCLAF1 form a transcription repression complex in colorectal cancer cells, identified by LC-MS/MS, co-IP, immunofluorescence colocalization, and proximity ligation assays. The TET2-BCLAF1 complex binds to the Ascl2 promoter and restrains its hypermethylation by inducing hydroxymethylation at CCGG sites, regulating Ascl2-dependent stem gene expression.\",\n      \"method\": \"LC-MS/MS, Co-IP, immunofluorescence colocalization, PLA, ChIP-qPCR, glucosylated hydroxymethyl-sensitive qPCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complex identified by MS and multiple orthogonal confirmation methods; direct epigenetic mechanism defined\",\n      \"pmids\": [\"35660018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCLAF1 regulates smooth muscle cell (SMC) survival and lipid transdifferentiation in atherosclerosis. BCLAF1 silencing leads to downregulation of BCL2 and SMC markers, reduced proliferation, and increased apoptosis. BCLAF1 interacts with BCL2 by proximity ligation assay in CD68+ cells of SMC origin in plaques. BCLAF1 knockdown prevents oxLDL-induced SMC transdifferentiation to macrophage-like phenotype.\",\n      \"method\": \"siRNA knockdown, proximity ligation assay, immunohistochemistry, MYH11 lineage-tracing atherosclerotic mice\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — PLA interaction, functional knockdown, in vivo lineage tracing; single lab\",\n      \"pmids\": [\"35321563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cross-linking mass spectrometry (XL-MS) of endogenous proteins revealed that Bclaf1, Thrap3, and Erh interact closely with each other, with interaction surfaces mapped to non-disordered portions of these largely disordered proteins, suggesting they form a novel TEB complex.\",\n      \"method\": \"Cross-linking mass spectrometry (XL-MS) with DSSO crosslinker after immunoprecipitation of endogenous proteins\",\n      \"journal\": \"Wellcome open research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structural topology of endogenous complex by XL-MS, but single method and no functional follow-up\",\n      \"pmids\": [\"35865489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCLAF1 interacts with Cullin 3 (CUL3), and through this interaction BCLAF1 promotes ubiquitination and degradation of PHD2 (prolyl hydroxylase domain protein 2), leading to HIF-1α accumulation under normoxic conditions and upregulation of PD-L1 transcription.\",\n      \"method\": \"Co-IP, immunofluorescence, Western blot, RT-qPCR, ubiquitination assay\",\n      \"journal\": \"Cancer immunology, immunotherapy : CII\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, Co-IP-based interaction with functional downstream readout\",\n      \"pmids\": [\"37906282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCLAF1 interacts with YTHDF2 (an m6A reader protein) in esophageal squamous cell carcinoma, as identified by mass spectrometry, co-immunoprecipitation, and GST pull-down. BCLAF1 reduces YTHDF2 tumor-suppressive activity, and this promotes SIX1 mRNA stability and expression (via reduced m6A-dependent degradation), enhancing glycolysis and cancer progression.\",\n      \"method\": \"Mass spectrometry, Co-IP, GST pull-down, MeRIP-seq, RIP-seq, transcriptomic analysis\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — interaction confirmed by multiple methods including GST pull-down and MeRIP-seq for mechanism\",\n      \"pmids\": [\"38636894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCLAF1 interacts with BACH1 (BRCA1-associated C-terminal helicase) constitutively; upon DNA damage, BCLAF1 is recruited to DNA damage sites in a BACH1- and BRCA1-dependent manner. BCLAF1-deficient cells are defective in DSB-initiated homologous recombination (HR), although RAD51 foci formation is intact.\",\n      \"method\": \"Tandem protein affinity purification, Co-IP, immunofluorescence (DNA damage foci), siRNA knockdown, HR reporter assay\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction and recruitment defined, genetic epistasis for HR, single lab\",\n      \"pmids\": [\"35930920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCLAF1 interacts with LAMTOR2, and this interaction regulates the nuclear translocation of BCLAF1. In osteoarthritis, BCLAF1 is upregulated in chondrocytes and promotes catabolic gene expression and apoptosis; BCLAF1 knockdown via intra-articular adeno-associated virus attenuates cartilage degradation in vivo.\",\n      \"method\": \"Co-IP, mass spectrometry, subcellular fractionation, adenoviral shRNA in vivo, OA mouse model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — interaction identified by IP/MS with functional consequence, in vivo validation, single lab\",\n      \"pmids\": [\"39990659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MED23 (a mediator complex subunit) interacts with BCLAF1, and this MED23/BCLAF1 complex regulates NUPR1 transcription in NSCLC cells. Loss of MED23 triggers premature senescence through disrupted autophagic flux dependent on NUPR1 expression downstream of the complex.\",\n      \"method\": \"Co-IP, mass spectrometry, PLA, RNA-seq, ChIP assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — interaction validated by co-IP and PLA, downstream target validated by ChIP, single lab\",\n      \"pmids\": [\"39366174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nuclear p85β (regulatory subunit of PI3K) physically interacts with BCLAF1 and co-occupies gene loci genome-wide. BCLAF1 recruits p85β to BCLAF1 gene loci, and p85β facilitates assembly of BCLAF1, TRIM28, and ZNF263 to activate BCLAF1 transcription in a positive autoregulatory loop. This nuclear function of p85β/BCLAF1 contributes to oncogenic gene transcription.\",\n      \"method\": \"Multi-omics (ChIP-seq, proteomics), Co-IP, knockdown, reporter assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multi-omics co-occupancy, direct interaction, autoregulatory mechanism with multiple validations\",\n      \"pmids\": [\"40016211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCLAF1 physically associates with core spliceosome components and regulates alternative splicing with a predominant effect on intron retention. BCLAF1 is required for productive splicing of ATF4 mRNA, thereby sustaining ATF4 protein expression. Loss of BCLAF1 reduces ATF4 protein levels, downregulates metabolic target genes, disrupts de novo amino acid biosynthesis, and sensitizes AML cells to venetoclax.\",\n      \"method\": \"Co-IP (spliceosome components), RNA-seq splicing analysis, BCLAF1 depletion, ATF4 protein/mRNA analysis, metabolic assays, drug sensitivity assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — preprint with direct interaction, splicing mechanism, and metabolic consequence; awaiting peer review\",\n      \"pmids\": [\"41648520\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bclaf1 undergoes liquid-liquid phase separation (LLPS) in cardiomyocytes under oxidative stress, forming biomolecular condensates in the nucleus that sequester PTK2 (FAK). PTK2 within Bclaf1 condensates is protected from ubiquitin-proteasome system (UPS)-mediated degradation at the K926 ubiquitination site. Disruption of Bclaf1 condensates leads to PTK2 degradation, increased p53 levels, and apoptosis.\",\n      \"method\": \"Advanced fluorescence microscopy (LLPS visualization), Co-IP, ubiquitination site mapping (K926), proteasome inhibition, Bclaf1 knockdown\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2-3 — preprint, novel LLPS mechanism; awaiting peer review and independent replication\",\n      \"pmids\": [\"bio_10.1101_2025.02.04.636487\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCKDK (branched-chain ketoacid dehydrogenase kinase) interacts with BCLAF1 and promotes its phosphorylation at serine 285, which facilitates BCLAF1 binding to the MYC promoter to enhance MYC transcription, driving HK2-dependent aerobic glycolysis and Trametinib resistance in lung cancer.\",\n      \"method\": \"Co-IP, phosphorylation assay (S285 site), ChIP at MYC promoter, BCKDK/BCLAF1 knockdown, glycolysis assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction, phosphorylation site identified, ChIP validation; single lab\",\n      \"pmids\": [\"40442441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Depletion of Btf (BCLAF1) and/or TRAP150 causes mitotic chromosome misalignment defects in human cells, associated with altered abundance of transcripts encoding mitotic checkpoint regulators, indicating BCLAF1 controls mitotic progression through regulating mitotic regulator mRNA levels.\",\n      \"method\": \"siRNA knockdown, live-cell microscopy, RT-PCR for mitotic regulator transcripts\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct functional link between BCLAF1 depletion and mitotic defects, but mechanistic detail limited to transcript levels\",\n      \"pmids\": [\"28895891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bclaf1 promotes chromatin accessibility in esophageal carcinogenesis by activating POLR2A (RNA polymerase II subunit) through two mechanisms: (1) transcriptionally, Bclaf1/P300/H3K27ac co-recruitment at the POLR2A super-enhancer (E2/E3 elements) drives transcription; (2) post-transcriptionally, Bclaf1 cofactor SNRPA interacts with pre-POLR2A mRNA to regulate its splicing.\",\n      \"method\": \"ATAC-seq, CUT&Tag, RIP assay, ChIP, siRNA knockdown, ATAC-seq after Bclaf1 silencing\",\n      \"journal\": \"Journal of hazardous materials\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple epigenomic methods defining dual transcriptional/splicing mechanism; single lab\",\n      \"pmids\": [\"40220379\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCLAF1 is a multifunctional nuclear protein that acts as a transcriptional activator or repressor (via its bZIP domain), an mRNA splicing regulator associated with the spliceosome, and an mRNA stability/export factor; it interacts with Bcl-2 family members, NF-κB subunits (p50/p65), STAT2, HIF-1α, SPOP E3 ligase, the EJC, PP1/SDS22, and multiple splicing factors to regulate apoptosis, the DNA damage response (via γH2AX/Ku70/DNA-PKcs and NHEJ), type I interferon signaling, cellular senescence, hypoxic adaptation (HIF-1α stabilization), immune checkpoint (PD-L1 stabilization via SPOP competition), and developmental processes including lung morphogenesis, T-cell activation, and B-cell development.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BCLAF1 is a multifunctional nuclear protein that integrates transcriptional regulation, mRNA splicing, and mRNA stability control across diverse cellular processes including apoptosis, the DNA damage response, immune signaling, hypoxic adaptation, and developmental programs. Through its bZIP-like domain, BCLAF1 activates or represses transcription at specific promoters — driving TP53 expression with PKCδ after genotoxic stress [PMID:17938203], CFLAR (c-FLIP) expression with NF-κB p50 to restrain TNF-induced apoptosis [PMID:34693625], HIF1A in a positive feedback loop under hypoxia [PMID:30367150, PMID:32029898], and IL-6/IL-8 with C/EBPβ during therapy-induced senescence [PMID:26794446] — while also forming transcription factor complexes with SPIC to regulate B-cell development [PMID:31644907], with TET2 to control promoter hydroxymethylation [PMID:35660018], and with p85β/TRIM28/ZNF263 in an autoregulatory circuit [PMID:40016211]. BCLAF1 additionally associates with spliceosome components and the THRAP3/ERH complex to regulate alternative splicing and nuclear export of transcripts critical for the DNA damage response, mitotic fidelity, and metabolic homeostasis, including ATM kinase and ATF4 mRNAs [PMID:29112714, PMID:35865489], and stabilizes specific mRNAs such as cyclin D1 downstream of the circadian regulator CRY2 [PMID:29466738]. Knockout mice reveal requirements for lung smooth muscle morphogenesis and peripheral T-cell homeostasis independent of a simple proapoptotic role, while BCLAF1 also functions as a viral restriction factor neutralized by HCMV and alphaherpesviruses [PMID:19008920, PMID:22645331, PMID:30682178].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The discovery of BCLAF1 established it as a Bcl-2/Bcl-xL-interacting nuclear protein with DNA-binding and transcriptional repression activity whose overexpression induces apoptosis, providing the founding link between anti-apoptotic Bcl-2 family members and a transcription factor.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro DNA binding, reporter assays, and overexpression apoptosis assays in HeLa cells\",\n      \"pmids\": [\"10330179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous transcriptional targets unidentified\", \"Mechanism of Bcl-2/Bcl-xL cytoplasmic sequestration unclear at molecular level\", \"Physiological relevance of proapoptotic activity not tested in vivo\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of emerin as a high-affinity BCLAF1 binding partner, with a disease-causing emerin mutation selectively disrupting this interaction, revealed that BCLAF1 connects to nuclear envelope biology and suggested its subnuclear relocalization during apoptosis.\",\n      \"evidence\": \"Yeast two-hybrid, biochemical affinity measurement (KD ~100 nM), mutagenesis, immunofluorescence during Fas-induced apoptosis\",\n      \"pmids\": [\"15009215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of emerin-BCLAF1 interaction on gene expression undefined\", \"Whether BCLAF1 contributes to Emery-Dreifuss muscular dystrophy pathogenesis untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that PKCδ partners with BCLAF1 at the TP53 promoter after DNA damage established BCLAF1 as a direct transcriptional activator of a specific endogenous target (TP53), resolving the question of what genes BCLAF1 regulates.\",\n      \"evidence\": \"ChIP, Co-IP, reporter assays, RNAi knockdown, RT-PCR in genotoxically stressed cells\",\n      \"pmids\": [\"17938203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCLAF1 binds TP53 promoter independently of PKCδ unknown\", \"Genome-wide scope of BCLAF1 transcriptional targets not yet mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Bclaf1 knockout mice revealed essential developmental roles in lung morphogenesis and peripheral T-cell homeostasis but no overt apoptosis defect, fundamentally reframing BCLAF1 from a dedicated proapoptotic factor to a pleiotropic regulator.\",\n      \"evidence\": \"Targeted gene knockout in mice, histology, FACS analysis\",\n      \"pmids\": [\"19008920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets mediating lung and T-cell phenotypes not identified\", \"Conditional tissue-specific knockouts not performed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placing BCLAF1 as a Sirt1/NF-κB-regulated downstream effector in T-cell activation explained how BCLAF1 transcription itself is controlled and linked it to chromatin remodeling (H3K56 acetylation) at its own promoter.\",\n      \"evidence\": \"ChIP for H3K56ac, siRNA epistasis, IL-2 ELISA in Sirt1-null T cells\",\n      \"pmids\": [\"21454709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Sirt1-BCLAF1 axis operates outside T cells unclear\", \"Downstream BCLAF1 targets in T-cell activation undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two parallel advances established BCLAF1's roles in DNA damage signaling — promoting γH2AX-associated NHEJ repair via Ku70/DNA-PKcs stabilization — and in antiviral defense, where HCMV evolved two independent strategies (pp71/UL35-mediated degradation and miR-UL112-1 silencing) to neutralize BCLAF1 as a restriction factor.\",\n      \"evidence\": \"MS-based identification, Co-IP, colocalization with γH2AX, siRNA knockdown for DDR; viral infection assays, proteasome inhibitors, miRNA assays for HCMV\",\n      \"pmids\": [\"22833098\", \"22645331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCLAF1 participates in HR in addition to NHEJ not addressed\", \"Identity of BCLAF1-regulated antiviral genes not determined\", \"Structural basis of Ku70/DNA-PKcs stabilization unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Localization of BCLAF1 at active transcription loci in an RNA Pol II-dependent manner, overlapping with EJC component Magoh, and the finding that its depletion increases cytoplasmic mRNA levels, established BCLAF1 as a regulator of mRNA subcellular distribution beyond its transcription factor role.\",\n      \"evidence\": \"Live-cell imaging at reporter loci, nuclear/cytoplasmic fractionation, RT-PCR after siRNA knockdown\",\n      \"pmids\": [\"23778535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BCLAF1 directly binds mRNA or acts indirectly through EJC not resolved\", \"Specificity of affected transcripts not determined genome-wide\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The demonstration that SRSF10 drives inclusion of BCLAF1 exon 5a to generate an oncogenic isoform in colorectal cancer showed that BCLAF1 function is itself regulated by alternative splicing, adding isoform-level complexity.\",\n      \"evidence\": \"RT-PCR splicing assays, knockdown/overexpression, tumor growth assays in colon cancer cells and patient samples\",\n      \"pmids\": [\"25091051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional domain encoded by exon 5a not biochemically characterized\", \"Whether other BCLAF1 isoforms have distinct functions unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying BCLAF1 as a bridge between NF-κB and C/EBPβ to drive the senescence-associated secretory phenotype (IL-6/IL-8) established a new cell-fate role for BCLAF1 in therapy-induced senescence.\",\n      \"evidence\": \"ChIP, Co-IP, reporter assays, IL-6/IL-8 ELISA, xenograft model after doxorubicin treatment\",\n      \"pmids\": [\"26794446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCLAF1 is required for all SASP components or only IL-6/IL-8 unclear\", \"Relationship between BCLAF1's senescence and apoptosis roles not delineated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Multiple studies converged to show BCLAF1 functions as a selective mRNA splicing/export factor for DDR transcripts (including ATM), and as a cofactor for type I interferon signaling through direct STAT2 interaction, broadening its role to RNA processing and innate immunity.\",\n      \"evidence\": \"RNA-seq splicing analysis, nuclear export assays, DNA damage sensitivity for DDR role; CRISPR/siRNA, Co-IP, ChIP at ISRE elements for IFN role; viral exploitation by alphaherpesvirus US3\",\n      \"pmids\": [\"29112714\", \"30682178\", \"28895891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full catalog of BCLAF1-dependent splicing events not defined\", \"Mechanism by which BCLAF1 selects specific transcripts for splicing regulation unknown\", \"Whether BCLAF1's IFN role extends to type II/III interferons not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery of a HIF-1α/BCLAF1 positive feedback loop under hypoxia — BCLAF1 transcribes HIF1A via its bZIP domain while HIF-1α reciprocally upregulates BCLAF1 — and identification of BCLAF1 as a CRY2-dependent mRNA stabilizer in myogenesis, demonstrated dual transcriptional and post-transcriptional functions in distinct biological contexts.\",\n      \"evidence\": \"ChIP, reporter assays with bZIP mutants, xenografts for hypoxia; Co-IP, RNA stability assays, Cry2 KO mice for myogenesis\",\n      \"pmids\": [\"30367150\", \"29466738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA-binding domains/motifs of BCLAF1 for mRNA stabilization not mapped\", \"Whether HIF-1α feedback operates in non-tumor contexts undetermined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Structural and functional advances revealed that BCLAF1 forms a transcription factor complex with SPIC to displace PU.1 genome-wide during B-cell development, and that phosphorylated BCLAF1 binds the PP1/SDS22 phosphatase complex, identifying post-translational regulation of BCLAF1.\",\n      \"evidence\": \"ChIP-seq, Co-IP, genetic epistasis in pre-B cells for SPIC complex; X-ray crystallography of SDS22, biochemical binding for PP1\",\n      \"pmids\": [\"31644907\", \"30661852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which phosphorylation sites on BCLAF1 are regulated by PP1/SDS22 undefined\", \"Whether SPIC/BCLAF1 complex operates outside B cells unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR knockout confirmed BCLAF1 stabilizes HIF-1α protein in the nucleus during sustained hypoxia, validating the positive feedback loop with genetic loss-of-function and in vivo xenograft evidence.\",\n      \"evidence\": \"CRISPR knockout, Co-IP, protein stability assays, xenograft tumor growth measurement\",\n      \"pmids\": [\"32029898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of HIF-1α stabilization by BCLAF1 unresolved\", \"Whether BCLAF1 protects HIF-1α from VHL-mediated or VHL-independent degradation not distinguished\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Two studies resolved context-dependent pro- vs anti-apoptotic roles: BCLAF1 promotes cardiomyocyte apoptosis after ischemia-reperfusion (sequestered by lncCIRBIL), while in TNF signaling it prevents apoptosis by activating CFLAR/c-FLIP transcription via NF-κB p50, explaining the long-standing paradox of its dual roles.\",\n      \"evidence\": \"Transgenic/KO mouse epistasis for cardiac I/R; Co-IP, ChIP at CFLAR promoter, TNF-induced apoptosis assays, in vivo siRNA for TNF pathway\",\n      \"pmids\": [\"33483496\", \"34693625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What determines pro- vs anti-apoptotic output in a given cell type not defined\", \"Post-translational modifications dictating context-dependent function not mapped systematically\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of BCLAF1 as a competitive inhibitor of SPOP-mediated PD-L1 ubiquitination through a defined SBC motif, and as a TET2 partner regulating promoter hydroxymethylation, expanded BCLAF1 into immune checkpoint regulation and epigenetic control.\",\n      \"evidence\": \"Site-directed mutagenesis of SBC motif, ubiquitination competition assay, T-cell cytotoxicity for SPOP/PD-L1; LC-MS/MS, PLA, ChIP-qPCR, glucosylated hydroxymethyl-qPCR for TET2\",\n      \"pmids\": [\"38340178\", \"35660018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of BCLAF1-SPOP axis for anti-tumor immunity not tested\", \"Genome-wide scope of TET2-BCLAF1 hydroxymethylation targets unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cross-linking mass spectrometry defined the BCLAF1-THRAP3-ERH (TEB) complex topology, mapping interaction surfaces to ordered regions within these largely disordered proteins and suggesting a stable ternary complex as the functional unit for RNA processing.\",\n      \"evidence\": \"XL-MS with DSSO crosslinker after immunoprecipitation of endogenous proteins\",\n      \"pmids\": [\"35865489\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional validation of TEB complex as a unit is absent\", \"No reconstitution or structural model beyond crosslink restraints\", \"Stoichiometry and dynamics of the complex unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Multiple studies expanded the BCLAF1 interaction network: BACH1/BRCA1-dependent recruitment to DNA damage sites for homologous recombination, YTHDF2 antagonism to stabilize m6A-modified mRNAs, LAMTOR2-regulated nuclear translocation, and MED23 partnership for NUPR1 transcription, each linking BCLAF1 to additional pathways.\",\n      \"evidence\": \"Tandem affinity purification and HR reporter for BACH1; MS, Co-IP, GST pull-down, MeRIP-seq for YTHDF2; Co-IP, fractionation, OA mouse model for LAMTOR2; Co-IP, PLA, ChIP for MED23\",\n      \"pmids\": [\"35930920\", \"38636894\", \"39990659\", \"39366174\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which BCLAF1 participates in HR downstream of RAD51 foci undefined\", \"Whether BCLAF1-YTHDF2 interaction is direct and stoichiometric needs further validation\", \"Selectivity of LAMTOR2 regulation of BCLAF1 nuclear entry unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Recent work revealed that nuclear p85β recruits BCLAF1 into an autoregulatory transcriptional loop with TRIM28/ZNF263, BCKDK phosphorylates BCLAF1 at S285 to promote MYC transcription and glycolysis, and BCLAF1 activates POLR2A through dual transcriptional and splicing mechanisms — collectively demonstrating that BCLAF1 is itself a hub for multiple upstream kinase and cofactor inputs.\",\n      \"evidence\": \"ChIP-seq/proteomics for p85β; Co-IP, S285 phosphorylation, ChIP at MYC promoter for BCKDK; ATAC-seq, CUT&Tag, RIP for POLR2A regulation\",\n      \"pmids\": [\"40016211\", \"40442441\", \"40220379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether S285 phosphorylation by BCKDK occurs in non-cancer contexts not known\", \"Complete phosphoproteome map of BCLAF1 lacking\", \"Whether POLR2A regulation is a direct or indirect consequence of BCLAF1's general splicing role unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A comprehensive structural model of full-length BCLAF1, the rules governing its context-dependent switch between pro- and anti-apoptotic outputs, and the relative contributions of its transcriptional versus RNA-processing functions in each physiological setting remain to be established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of full-length BCLAF1 or its key domains beyond bZIP homology\", \"Systematic mapping of post-translational modifications and their functional consequences incomplete\", \"No unified model explaining how one protein integrates transcription, splicing, and mRNA stability in a context-dependent manner\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 9, 12, 14, 18, 28, 31]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 11, 12]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [7, 10, 13, 29, 33]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [19, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 2, 7, 11, 14, 16, 17, 20, 28]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [7, 14, 15, 28]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [5, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 9, 12, 14, 18, 28, 31, 33]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [7, 8, 10, 29, 33]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [5, 10, 25]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 2, 5, 17, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 11, 19]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [9, 12, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 14]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 20]}\n    ],\n    \"complexes\": [\n      \"BCLAF1-THRAP3-ERH (TEB) complex\",\n      \"SPIC-BCLAF1 transcription factor complex\",\n      \"TET2-BCLAF1 complex\",\n      \"p85β-BCLAF1-TRIM28-ZNF263 complex\"\n    ],\n    \"partners\": [\n      \"THRAP3\",\n      \"SPIC\",\n      \"SPOP\",\n      \"HIF1A\",\n      \"NFKB1\",\n      \"STAT2\",\n      \"BACH1\",\n      \"CRY2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}